Trial reportBlood2013
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.
Trial report in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Bone Marrow Harvest: A White Paper of Best Practices by the NMDP Marrow Alliance.Transplantation and cellular therapy · 2024Guideline
- Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee.Bone marrow transplantation · 2014Guideline
- Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials.Transplantation and cellular therapy · 2022Trial
- Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.Haematologica · 2019Trial
- Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
- Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Trial
- Health-related quality of life of bone marrow versus peripheral blood stem cell donors: a prespecified subgroup analysis from a phase III RCT-BMTCTN protocol 0201.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014Trial
- Review
- Hematopoietic Stem Cell Donors' Experiences of Information and Side-Effects During the First Year After Donation-A Swedish National Study.Journal of clinical apheresis · 2025Article
- Graft Source Choice.Advances in experimental medicine and biology · 2025Review
- The role of immune cells settled in the bone marrow on adult hematopoietic stem cells.Cellular and molecular life sciences : CMLS · 2024Review
- Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim.Blood advances · 2024Observational
- Psychological and physical side effects during G-CSF mobilization in related donors of allo-HCT.Annals of hematology · 2024Article
- Trading tissues for freedom: incentivizing stem cell and solid organ donation in the incarcerated population.Bone marrow transplantation · 2023Article
- Dental Pulp Stem Cells for Bone Tissue Engineering: A Literature Review.Stem cells international · 2023Review
- Comparison between peripheral blood progenitor cell collection on the 4Blood transfusion = Trasfusione del sangue · 2023Article
- Increased serum pro-B-type natriuretic peptide in hematopoietic progenitor cell donors stimulated with G-CSF.Journal of clinical apheresis · 2022Article
- Decreased Opioid Consumption in Bone Marrow Harvest Patients Using Quadratus Lumborum Blocks in a Standardized Protocol.Frontiers in medicine · 2022Article
- Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma.Stem cell reviews and reports · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
21 authors.
Funding
Abstract
Although peripheral blood stem cells (PBSCs) have replaced bone marrow (BM) as the most common unrelated donor progenitor cell product collected, a direct comparison of concurrent PBSC versus BM donation experiences has not been performed. We report a prospective study of 2726 BM and 6768 PBSC donors who underwent collection from 2004 to 2009. Pain and toxicities were assessed at baseline, during G-CSF administration, on the day of collection, within 48 hours of donation, and weekly until full recovery. Peak levels of pain and toxicities did not differ between the 2 donation processes for most donors. Among obese donors, PBSC donors were at increased risk of grade 2 to 4 pain as well as grade 2 to 4 toxicities during the pericollection period. In contrast, BM donors were more likely to experience grade 2 to 4 toxicities at 1 week and pain at 1 week and 1 month after the procedure. BM donors experienced slower recovery, with 3% still not fully recovered at 24 weeks, whereas 100% of PBSC donors had recovered. Other factors associated with toxicity included obesity, increasing age, and female sex. In summary, this study provides extensive detail regarding individualized risk patterns of PBSC versus BM donation toxicity, suggesting donor profiles that can be targeted with interventions to minimize toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.